SECURITIES AND EXCHANGE COMMISSIONSEC FORM 17-A, AS AMENDED

ANNUAL REPORT PURSUANT TO SECTION 17
OF THE SECURITIES REGULATION CODE AND SECTION 141
OF THE CORPORATION CODE OF THE PHILIPPINES

1. For the fiscal year ended

Dec 31, 2024

2. SEC Identification Number

148022

3. BIR Tax Identification No.

000-288-655-000

4. Exact name of issuer as specified in its charter

Euro-Med Laboratories Phil., Inc.

5. Province, country or other jurisdiction of incorporation or organization

Metro Manila

6. Industry Classification Code(SEC Use Only)

7. Address of principal office

PPL Building, United Nations Avenue corner San Marcelino St., Manila Postal Code 1007

8. Issuer's telephone number, including area code

00-63-2-85240091 to 98

9. Former name or former address, and former fiscal year, if changed since last report

N/A

10. Securities registered pursuant to Sections 8 and 12 of the SRC or Sections 4 and 8 of the RSA

Title of Each Class	Number of Shares of Common Stock Outstanding and Amount of Debt Outstanding
common shares	4,112,140,540

11. Are any or all of registrant's securities listed on a Stock Exchange?

Yes

No

If yes, state the name of such stock exchange and the classes of securities listed therein:

The Philippine Stock Exchange, Inc.

12. Check whether the issuer:

(a) has filed all reports required to be filed by Section 17 of the SRC and SRC Rule 17.1 thereunder or Section 11 of the RSA and RSA Rule 11(a)-1 thereunder, and Sections 26 and 141 of The Corporation Code of the Philippines during the preceding twelve (12) months (or for such shorter period that the registrant was required to file such reports)

Yes

No

(b) has been subject to such filing requirements for the past ninety (90) days

Yes

No

13. State the aggregate market value of the voting stock held by non-affiliates of the registrant. The aggregate market value shall be computed by reference to the price at which the stock was sold, or the average bid and asked prices of such stock, as of a specified date within sixty (60) days prior to the date of filing. If a determination as to whether a particular person or entity is an affiliate cannot be made without involving unreasonable effort and expense, the aggregate market value of the common stock held by non-affiliates may be calculated on the basis of assumptions reasonable under the circumstances, provided the assumptions are set forth in this Form

N/A

APPLICABLE ONLY TO ISSUERS INVOLVED IN INSOLVENCY SUSPENSION OF PAYMENTS PROCEEDINGS DURING THE PRECEDING FIVE YEARS

14. Check whether the issuer has filed all documents and reports required to be filed by Section 17 of the Code subsequent to the distribution of securities under a plan confirmed by a court or the Commission.

Yes

No

DOCUMENTS INCORPORATED BY REFERENCE

15. If any of the following documents are incorporated by reference, briefly describe them and identify the part of SEC Form 17-A into which the document is incorporated:

(a) Any annual report to security holders

N/A

(b) Any information statement filed pursuant to SRC Rule 20

N/A

(c) Any prospectus filed pursuant to SRC Rule 8.1

N/A

The Exchange does not warrant and holds no responsibility for the veracity of the facts and representations contained in all corporate disclosures, including financial reports. All data contained herein are prepared and submitted by the disclosing party to the Exchange, and are disseminated solely for purposes of information. Any questions on the data contained herein should be addressed directly to the Corporate Information Officer of the disclosing party.

Euro-Med Laboratories Phil., Inc.EURO

PSE Disclosure Form 17-1 - Annual Report References: SRC Rule 17 and
Section 17.2 and 17.8 of the Revised Disclosure Rules

For the fiscal year ended	Dec 31, 2024
Currency	Php

Balance Sheet

	Year Ending	Previous Year Ending
	Dec 31, 2024	Dec 31, 2023
Current Assets	5,318,058,680	5,135,417,492
Total Assets	10,949,904,739	10,763,917,993
Current Liabilities	3,909,260,781	3,918,103,074
Total Liabilities	5,067,004,801	4,918,730,015
Retained Earnings/(Deficit)	1,723,917,468	1,691,589,188
Stockholders' Equity	5,882,899,938	5,845,187,978
Stockholders' Equity - Parent	5,806,576,087	5,772,284,945
Book Value Per Share	1.43	1.42

Income Statement

	Year Ending	Previous Year Ending
	Dec 31, 2024	Dec 31, 2023
Gross Revenue	5,796,044,756	5,263,939,460
Gross Expense	5,127,015,104	4,611,363,056
Non-Operating Income	87,794,762	40,057,855
Non-Operating Expense	319,365,184	294,237,619
Income/(Loss) Before Tax	437,459,230	398,396,640
Income Tax Expense	99,781,543	108,449,724
Net Income/(Loss) After Tax	337,677,687	289,946,916
Net Income/(Loss) Attributable to Parent Equity Holder	334,861,399	290,139,840
Earnings/(Loss) Per Share (Basic)	0.08	0.05
Earnings/(Loss) Per Share (Diluted)	0.08	0.05

Financial Ratios

	Formula	Fiscal Year Ended	Previous Fiscal Year
		Dec 31, 2024	Dec 31, 2023
Liquidity Analysis Ratios:
Current Ratio or Working Capital Ratio	Current Assets / Current Liabilities	1.36	1.31
Quick Ratio	(Current Assets - Inventory - Prepayments) / Current Liabilities	0.83	0.65
Solvency Ratio	Total Assets / Total Liabilities	0.13	0.12
Financial Leverage Ratios
Debt Ratio	Total Debt/Total Assets	0.46	0.46
Debt-to-Equity Ratio	Total Debt/Total Stockholders' Equity	0.86	0.84
Interest Coverage	Earnings Before Interest and Taxes (EBIT) / Interest Charges	3.53	3.59
Asset to Equity Ratio	Total Assets / Total Stockholders' Equity	1.86	1.84
Profitability Ratios
Gross Profit Margin	Sales - Cost of Goods Sold or Cost of Service / Sales	0.35	0.36
Net Profit Margin	Net Profit / Sales	0.06	0.07
Return on Assets	Net Income / Total Assets	0.03	0.03
Return on Equity	Net Income / Total Stockholders' Equity	0.03	0.05
Price/Earnings Ratio	Price Per Share / Earnings Per Common Share	0.08	0.07

Other Relevant Information
Please see Note 26/27 (page 93) for breakdown of non-operating income and non-operating expense